×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRVS – corvus pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
04:01 pm
crvs
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Low
Report
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
1/12
07:05 am
crvs
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
Low
Report
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
1/5
09:15 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
12/11
10:04 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/8
10:30 am
crvs
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Medium
Report
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
11/9
10:49 am
crvs
Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]
11/4
04:13 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
04:01 pm
CRVS
corvus pharmaceuticals, inc.
BEAT
Report
-1.4%
corvus pharmaceuticals, inc.
8/7/2025
04:01 pm
CRVS
corvus pharmaceuticals, inc.
BEAT
Report
4.4%
corvus pharmaceuticals, inc.
5/8/2025
04:02 pm
CRVS
corvus pharmaceuticals, inc.
IN-LINE
Report
27.3%
corvus pharmaceuticals, inc.
5/8/2025
04:02 pm
CRVS
corvus pharmaceuticals, inc.
IN-LINE
Report
27.3%
corvus pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/8
04:23 pm
crvs
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: Jones William Benton
Low
Report
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: Jones William Benton
12/8
04:22 pm
crvs
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: LEA LEIV
Low
Report
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: LEA LEIV
12/8
04:22 pm
crvs
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: Arcara Jeffrey
Low
Report
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: Arcara Jeffrey
12/8
04:22 pm
crvs
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: MILLER RICHARD A MD
Low
Report
Form 4 Corvus Pharmaceuticals, For: Dec 04 Filed by: MILLER RICHARD A MD
11/4
04:03 pm
crvs
Form 10-Q Corvus Pharmaceuticals, For: Sep 30
Low
Report
Form 10-Q Corvus Pharmaceuticals, For: Sep 30
11/4
04:01 pm
crvs
Form 8-K Corvus Pharmaceuticals, For: Nov 04
Low
Report
Form 8-K Corvus Pharmaceuticals, For: Nov 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/2
Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
25.5%
7/1 Form 4 Corvus Pharmaceuticals, For: Jun 27 Filed by: ORBIMED ADVISORS LLC 21.0%
8/8 Form 4 Corvus Pharmaceuticals, For: Aug 06 Filed by: MILLER RICHARD A MD 20.7%
11/4 Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019 12.4%
3/20 Form EFFECT Corvus Pharmaceuticals, 12.3%
12/16 Form 4 Corvus Pharmaceuticals, For: Dec 12 Filed by: Hunt Daniel W. 10.6%
11/14 Form 4 Corvus Pharmaceuticals, For: Nov 12 Filed by: MILLER RICHARD A MD 9.9%
4/15 Form DEF 14A Corvus Pharmaceuticals, For: Jun 09 7.3%
10/17 Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019 6.7%
5/9 Q1/2019 3/31/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.1%
7/1 Form 4 Corvus Pharmaceuticals, For: Jun 27 Filed by: ORBIMED ADVISORS LLC 21.0%
8/8 Form 4 Corvus Pharmaceuticals, For: Aug 06 Filed by: MILLER RICHARD A MD 20.7%
11/4 Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019 12.4%
3/20 Form EFFECT Corvus Pharmaceuticals, 12.3%
12/16 Form 4 Corvus Pharmaceuticals, For: Dec 12 Filed by: Hunt Daniel W. 10.6%
11/14 Form 4 Corvus Pharmaceuticals, For: Nov 12 Filed by: MILLER RICHARD A MD 9.9%
4/15 Form DEF 14A Corvus Pharmaceuticals, For: Jun 09 7.3%
10/17 Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019 6.7%
5/9 Q1/2019 3/31/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.1%
TOP News Decliners
4/30
Form 10-Q Corvus Pharmaceuticals, For: Mar 31
-13.7%
3/5 Q4/2019 12/31/2019 EPS -0.380 ZacksConsensus -0.330 ActVsEst (0.050) - Miss -12.5%
3/20 Form 424B5 Corvus Pharmaceuticals, -11.4%
7/15 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
11/12 Form 8-K Corvus Pharmaceuticals, For: Nov 08 -9.3%
2/13 Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium -9.3%
8/4 Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%
11/8 Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting -9.2%
12/31 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
9/12 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $7.00 price target on the stock. -8.2%
3/5 Q4/2019 12/31/2019 EPS -0.380 ZacksConsensus -0.330 ActVsEst (0.050) - Miss -12.5%
3/20 Form 424B5 Corvus Pharmaceuticals, -11.4%
7/15 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
11/12 Form 8-K Corvus Pharmaceuticals, For: Nov 08 -9.3%
2/13 Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium -9.3%
8/4 Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%
11/8 Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting -9.2%
12/31 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
9/12 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $7.00 price target on the stock. -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: